Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis

Peritoneal Dialysis International

Volumn 26, Issue 2, 2006, Pages 240-248

  Guz, Galip ^a   Colak, Bulent ^a   Hizel, Kenan ^a   Reis, Kadriye A ^a   Erten, Yasemin ^a   Bali, Musa ^a   Sindel, Sukru ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Inflammation markers; Peritonitis; Procalcitonin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; HEMOGLOBIN; PROCALCITONIN; CALCITONIN; PROTEIN PRECURSOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; CALCITONIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONITIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY;

EID: 33747141514     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600221     Document Type: Article

References (38)

1. Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984; 167:93-7.
2. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341(8844):515-18.
3. al-Nawas B, Shah PM. Procalcitonin in patients with and without immunosuppression and sepsis. Infection 1996; 24:434-6.
4. Bernard L, Ferriere F, Casassus P, Malas F, Leveque S, Guillevin L, et al. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis 1998; 27:914-15.
5. Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26:1001-6.
6. Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 1998; 26:274-6.
7. Level C, Chauveau P, Delmas Y, Lasseur C, Pelle G, Peuchant E, et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant 2001; 16:980-6.
8. Herget-Rosenthal S, Marggraf G, Pietruck F, Husing J, Strupat M, Philipp T, et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 2001; 16:975-9.
9. Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 2003; 29:579-83.
10. Schmidt M, Burchardi C, Sitter T, Held E, Schiffl H. Procalcitonin in patients undergoing chronic hemodialysis. Nephron 2000; 84:187-8.
11. D'Intini V, Bordoni V, Fortunato A, Galloni E, Carta M, Galli F, et al. Longitudinal study of apoptosis in chronic uremic patients. Semin Dial 2003; 16:467-73.
12. Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 2001; 18:79-87.
13. Al Nawas B, Krammer I, Shah PM. Procalcitonin in diagnosis of severe infections. Eur J Med Res 1996; 1:331-3.
14. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40:1250-6.
15. Eberhard OK, Langefeld I, Kuse ER, Brunkhorst FM, Kliem V, Schlift HJ, et al. Procalcitonin in the early phase after renaltransplantation - will it add to diagnostic accuracy? Clin Transplant 1998; 12:206-11.
16. Monneret G, Doche C, Durand DV, Lepape A, Bienvenu J. Procalcitonin as a specific marker of bacterial infection in adults. Clin Chem Lab Med 1998; 36:67-8.
17. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-8.
18. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med 1998; 24: 888-9.
19. Troidle L, Gorban-Brennan L, Kliger A, Finkelstein FO. Continuous peritoneal dialysis-associated peritonitis: a review and current concepts. Semin Dial 2003; 16:428-37.
20. Agroyannis B, Dalamangas A, Kopelias J, Tzanatos H, Fourtounas K, Bougatsos G, et al. Caution in the interpretation of erythrocyte sedimentation rate in haemodialysis and CAPD patients. Nephrol Dial Transplant 1994; 9:734-5.
21. Fine A. Relevance of C-reactive protein levels in peritoneal dialysis patients. Kidney Int 2002; 61:615-20.
22. Sliwinski AJ, Weber LD, Nashel DJ. C-reactive protein v erythrocyte sedimentation rate. A comparison of effectiveness as an infection marker in patients undergoing peritoneal dialysis. Arch Pathol Lab Med 1983; 107:387-8.
23. Vaziri ND, Shah GM, Winer RL, Gonzales E, Patel B, Alikhani S, et al. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989; 53:173-80.
24. Fein PA, Mittman N, Gadh R, Chattopadhyay J, Blaustein D, Mushnick R, et al. Malnutrition and inflammation in peritoneal dialysis patients. Kidney Int Suppl 2003; 87: S87-91.
25. Borazan A, Ustun H, Yilmaz A. The effects of haemodialysis and peritoneal dialysis on serum lipoprotein(a) and C-reactive protein levels. J Int Med Res 2003; 31:378-83.
26. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM. Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 1996; 16:158-62.
27. McIntyre C, Harper I, Macdougall IC, Raine AE, Williams A, Baker LR. Serum C-reactive protein as a marker for infection and inflammationin regular dialysis patients. Clin Nephrol 1997; 48:371-4.
28. Afzali B, Bakri RS, Bharma-Ariza P, Lumb PJ, Dalton N, Turner NC, et al. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. J Nephrol 2003; 16:540-5.
29. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137:133-9.
30. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritonealdialysis patients. Am J Kidney Dis 1996; 27:848-54.
31. Hind CR, Thomson SP, Winearls CG, Pepys MB. Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis. J Clin Pathol 1985; 38:459-63.
32. Kilger E, Pichler B, Goetz AE, Rank N, Welte M, Morstedt K, et al. Procalcitonin as a marker of systemic inflammation after conventional or minimally invasive coronary artery bypass grafting. Thorac Cardiovasc Surg 1998; 46:130-3.
33. Balog A, Ocsovszki I, Mandi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett 2002; 84:199-203.
34. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker E, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134:49-55.
35. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descampslatscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor. Kidney Int 1990; 37:116-25.
36. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28:458-61.
37. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1, TNF and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45:890-6.
38. Bossink AW, Groeneveld AB, Thijs LG. Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase-alpha-antitrypsin and lactoferrin compared with clinical variables. Clin Infect Dis 1999; 29:398-407.